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Nonalcoholic fatty liver disease (NAFLD) affects one
in three Americans and is a major predisposing
condition for the metabolic syndrome and type 2
diabetes (T2D). We examined whether a functionally
liver-targeted derivative of 2,4-dinitrophenol (DNP),
DNP-methyl ether (DNPME), could safely decrease
hypertriglyceridemia, NAFLD, and insulin resistance
without systemic toxicities. Treatment with DNPME
reversed hypertriglyceridemia, fatty liver, and whole-
body insulin resistance in high-fat-fed rats and
decreased hyperglycemia in a rat model of T2D with
a wide therapeutic index. The reversal of liver and
muscle insulin resistancewas associatedwith reduc-
tions in tissue diacylglycerol content and reductions
in protein kinase C epsilon (PKCε) and PKCq activity
in liver and muscle, respectively. These results de-
monstrate that thebeneficial effects ofDNPonhyper-
triglyceridemia, fatty liver, and insulin resistance can
be dissociated from systemic toxicities and suggest
the potential utility of liver-targeted mitochondrial
uncoupling agents for the treatment of hypertrigly-
ceridemia, NAFLD, metabolic syndrome, and T2D.
INTRODUCTION
Nonalcoholic fatty liver disease (NAFLD) is a key factor in the
pathogenesis of type 2 diabetes (T2D) and affects one in three
Americans (Petersen et al., 2005; Samuel and Shulman, 2012).
NAFLD is also a key predisposing factor for the development
of nonalcoholic steatohepatitis (NASH), cirrhosis, and hepato-
cellular carcinoma. Furthermore, it is anticipated that NAFLD-
induced NASH will soon surpass hepatitis C and alcoholic
cirrhosis as the most common indication for liver transplantation
in the US (White et al., 2012). Therefore, new and effective ther-
apies for treatment of NAFLD are urgently needed.740 Cell Metabolism 18, 740–748, November 5, 2013 ª2013 ElsevierWe hypothesized that a liver-targeted mitochondrial uncou-
pling agent might be an effective and safe approach for the
treatment of NAFLD and insulin resistance by promoting the
oxidation of hepatic triglyceride, while avoiding hyperthermia
and associated systemic toxicities that typically occur with
classic uncoupling agents. One of the best-characterized
mitochondrial uncoupling agents is 2,4 dinitrophenol (DNP), a
protonophore that shuttles protons across the mitochondrial
membrane, dissipating themitochondrial proton gradient and re-
sulting in the conversion of the energy derived from mitochon-
drial substrate oxidation to heat. DNP was extensively used as
a weight loss remedy in the 1930s but taken off the market by
the FDA in 1938 due to the occurrence of fatal hyperthermia.
Given that the toxicities of DNP are on-target effects related to
systemic mitochondrial uncoupling, we hypothesized that the
safety and therapeutic potential of DNP could be increased by
targeting DNP to the liver. We therefore synthesized and
screened liver-targeted DNP derivatives that would be preferen-
tially metabolized by liver and converted to DNP. In this screen,
we found that DNP-methyl ether (DNPME) both prevented and
reversed nonalcoholic fatty liver disease, insulin resistance,
and hyperglycemia in rat models of NAFLD and T2D without
hepatic or renal toxicity.RESULTS AND DISCUSSION
We hypothesized that targeting DNP to the liver would reduce
hypertriglyceridemia, hepatic lipid content, and improve insulin
sensitivity, without DNP-associated toxicities. We therefore
generated several derivatives of DNP, which we hypothesized
would be preferentially metabolized by the cytochrome P450
system in the liver to the active protonophore, DNP, and we
screened them in isolated hepatocytes for their ability to increase
oxygen consumption (Figures S1A and S1B available online).
From this screen, we identified two compounds that raised oxy-
gen consumption rates in plated hepatocytes with similar
potencies to DNP.We selected DNPME for further in vivo studies
due to its stability under acidic conditions, which would poten-
tially allow oral administration. In contrast to DNP, which causedInc.
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Effect of Liver-Targeted Mitochondrial Uncouplinga large, dose-dependent increase in rectal temperatures and
rapid dose-dependent mortality at doses above 10 mg/kg,
DNPME caused no such effects up to 200 mg/kg (Figures 1A–
1D). Thus, we found that the 50% lethal dose (LD50) of DNPME
was almost 10-fold higher than that of DNP (Figure 1E). Daily
treatment with DNPME for 5 days caused no appreciable hepatic
or renal toxicity at daily doses below 50 mg/kg (Figures 1F–1I),
but daily doses above 2.5 mg/kg were effective at reducing
hepatic triglyceride accumulation in rats fed a high-fat diet and
sucrose-supplemented (5%) drinking water (Figure 1J). In
contrast, the toxic threshold of chronic DNP treatment was
determined to be 1 mg/kg, whereas the lowest dose that was
effective at lowering liver triacylglycerol (TAG) was 5 mg/kg (Fig-
ures S1C–S1G); thus, the ratio of effective-to-toxic dose for DNP
was 0.2 compared to 10 for DNPME. From these data, we found
that DNPME had a favorable therapeutic index (lethal dose for
50% of the population [LD50]/minimum effective dose for 50%
of the population [ED50]) of 70, which compares favorably with
other drugs that are in common use, such as acetaminophen,
which has a LD50/ED50 of 13. We selected the lowest effective
daily dose of DNPME (5 mg/kg) to further characterize its effects
in vivo. Daily treatment at this dose for 6 weeks caused no differ-
ences in liver or renal function tests, liver or renal histology, or
rectal temperature (Figures 1K–1N, S1J, and S1K).
The safety and efficacy profiles of DNPME led us to examine
whether DNPME treatment could reverse preexisting hypertri-
glyceridemia, hepatic steatosis, and insulin resistance in a rat
model of NAFLD. To this end, we induced hepatic steatosis in
rats by feeding them a high-fat diet with sucrose-supplemented
drinking water, then treated them with DNPME or vehicle daily
for 5 days. The rats treated with DNPME had lower fasting
plasma glucose, triglyceride, and insulin concentrations
compared to the vehicle-treated animals (Figures 2A–2C),
despite identical body weight and food intake during the treat-
ment period (Figures S2A and S2B). Consistent with the reduced
fasting plasma glucose and insulin concentrations, DNPME-
treated rats had a 20% reduction in basal endogenous glucose
production (Figure 2D) and were muchmore glucose tolerant, as
reflected by 30%–70% reductions in plasma glucose and insulin
concentrations at each time point of an intraperitoneal (i.p.)
glucose tolerance test (Figures 2E, 2F, S2C, and S2D).
DNPME-treated rats also manifested increased whole-body
insulin responsiveness as reflected by a greater than 3-fold in-
crease in the glucose infusion rate required to maintain euglyce-
mia during a hyperinsulinemic-euglycemic clamp (Figures 2G
and S2E–S2G). This increase in insulin-stimulated whole-body
glucose metabolism in the DNPME-treated rats could be attrib-
uted to improvements in both hepatic and peripheral insulin
sensitivity (Figures 2H–2J). These improvements in hepatic
and peripheral insulin sensitivity were associated with 40%–
50% reductions in liver and muscle TAG (Figures 2K and 2L)
and diacylglycerol (DAG) content (Figure S2H–S2K). Consistent
with the reduced liver and muscle DAG concentration, we
observed reduced protein kinase C epsilon (PKCε) and PKCq
translocation in liver and muscle, respectively, in DNPME-
treated rats (Figures S2L and S2M), which is consistent with a
role for DAG-mediated novel protein kinase C (nPKC) activation
in causing the liver and muscle insulin resistance (Griffin et al.,
1999; Yu et al., 2002; Itani et al., 2002; Samuel et al., 2004,Cell M2007). In contrast, there were no differences in liver or muscle
ceramide content, liver glycogen content, plasma adiponectin,
FGF-21, or lactate concentrations, thus dissociating these fac-
tors from DNPME-induced improvements in liver and muscle
insulin sensitivity in these animals (Figures S2N–S2S). We also
examined the effect of DNPME on plasma markers of inflamma-
tion and found no effect of DNPME on any of these cytokines
other than a small reduction in plasma interleukin-13 (IL-13) con-
centrations (Figure S2T).
In the context of the observed reductions in muscle TAG and
DAG content and increases in skeletal muscle insulin sensitivity
observed with DNPME treatment, we examined whether these
effects of DNPME to lower muscle TAG and DAG content might
be explained by DNPME-induced reductions in hepatic very-
low-density lipoprotein (VLDL) production. Consistent with this
hypothesis, we observed a 50% reduction in hepatic VLDL pro-
duction with DNPME treatment (Figure 2M). In order to verify that
DNPME treatment reduced hepatic TAG/DAG content by pro-
moting increased hepatic mitochondrial uncoupling in vivo, we
measured liver-specific rates of oxidative flux pathways and
observed a 50% increase in rates of hepatic tricarboxylic acid
cycle flux (VTCA) (Figure 2N) after 1 and 5 days of DNPME treat-
ment. This increased hepatic mitochondrial VTCA flux was fueled
entirely by increased hepatic fatty acid oxidation flux on day 1
when liver fat content was unchanged between vehicle- and
DNPME-treated rats (18.2 ± 1.5 versus 16.9 ± 2.8 mg/kg, p =
0.70) but changed to an increase in mostly glucose oxidation,
through increased pyruvate dehydrogenase flux (VPDH) on day
5, when liver fat content normalized. This pyruvate dehydroge-
nase flux (VPDH)/VTCA flux observed on day 5 was similar to
that observed in the liver of normal chow-fed rats, whereas
VPDH/VTCA flux on days 0 and 1 was consistent with that of
high-fat-fed rats (Alves et al., 2011). Consistent with the reduced
fasting plasma glucose concentrations and basal rates of hepat-
ic glucose production in DNPME-treated rats after 5 days, these
animals also exhibited a 30% reduction in hepatic pyruvate
carboxylase flux (VPC) (Figure 2O), whereas there was no differ-
ence in VPC flux on the first day of DNPME treatment when liver
TAG content was unchanged. In contrast, the ratio of mitochon-
drial fatty acid oxidation to VTCA flux was unchanged by DNPME
treatment in all other tissues, including skeletal muscle (Fig-
ure 2P). While these relative flux measurements do not allow
us to rule out a small absolute increase in VTCA in peripheral tis-
sues, they are consistent with the hypothesis that the functional
effects of DNPME to raise oxygen consumption rate in vivo are
limited mostly to the liver.
Given the effects of DNPME to reduce ectopic lipid content in
liver and skeletal muscle and improve whole-body insulin sensi-
tivity in both the NAFLD prevention and reversal studies, we
examined whether DNPME treatment would improve fasting
and postprandial plasma glucose and insulin concentration pro-
files in a rat model of T2D. To evaluate this question, we exam-
ined the effect of 14 days of DNPME versus vehicle treatment
in a high-fat-fed and STZ-nicotinamide-treated rat model of
T2D (Masiello et al., 1998; Reed et al., 2000; Samuel et al.,
2004). Despite having no difference in body weight or white
adipose tissue (WAT) weight, and consistent with a primarily he-
patic uncoupling effect and unchanged whole-body metabolism
(Figures S3A and S3B), DNPME treatment normalized fastingetabolism 18, 740–748, November 5, 2013 ª2013 Elsevier Inc. 741
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Figure 1. Safety and Efficacy Profile of DNPME and DNP in Rats
(A and B) Rectal temperature following a single i.p. injection of DNP (A) or DNPME (B).
(C and D) Survival acutely following treatment with DNP (C) or DNPME (D).
(E) LD50 of DNP and DNPME.
(F–I) Plasma ALT (F), AST (G), BUN (H), and creatinine (I) after 5 days of daily treatment with DNPME or vehicle in chow-fed rats.
(J) Liver TAG in overnight-fasted rats after 5 days of daily treatment with DNPME during high-fat/sucrose water feeding.
(K–N) Liver and renal function tests: ALT (K), AST (L), BUN (M), and creatinine (N) after 6weeks of daily DNPME treatment (5mg/kg) in chow-fed rats. For all panels,
n = 4–6 per dose, and data are represented as mean ± SEM. See also Figure S1.
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Figure 2. DNPME Reverses NAFLD, Hypertriglyceridemia, and Liver and Muscle Insulin Resistance in Rats Fed High-Fat Diet and Sucrose
Water for 2 Weeks, then Treated with 5 mg/kg DNPME per Day for 5 Days
(A–C) Fasting plasma glucose (A), triglyceride (B), and insulin (C).
(D) Basal glucose turnover.
(E and F) Plasma glucose (E) and insulin (F) during an i.p. glucose tolerance test. Black circles, vehicle treated; red squares, DNPME treated. *p < 0.05, **p < 0.01,
***p < 0.001.
(G) Glucose infusion rate to maintain euglycemia during the hyperinsulinemic-euglycemic clamp.
(H) Insulin-stimulated glucose metabolism.
(I) Insulin-mediated suppression of hepatic glucose production.
(J) Insulin-stimulated glucose uptake in quadriceps.
(K and L) TAG in liver (K) and quadriceps (L).
(M) Liver VLDL production.
(N) Liver TCA cycle flux (sum of red and white bars) and substrate contributions (fatty acid oxidation, solid bar; PDH flux, white bar) to the TCA cycle. n = 3 vehicle
treated, 3 DNPME treated for 1 day, and 6 DNPME treated for 5 days.
(O) Hepatic flux through pyruvate carboxylase. Rats were fasted overnight prior to each of these studies.
(P) Fatty acid oxidation (% VTCA) in 1 day DNPME or vehicle-treated rats. Unless otherwise specified, n = 5–8 per group. Data are mean ± SEM. n = 3 vehicle
treated, 3 DNPME treated for 1 day, and 6 DNPME treated for 5 days. See also Figure S2.
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Effect of Liver-Targeted Mitochondrial Uncouplingplasma glucose and triglyceride concentrations (Figures 3A–3C).
DNPME treatment also resulted in a marked improvement in
glucose tolerance associated with lower plasma insulin concen-
trations, reflecting improved whole-body insulin sensitivity (Fig-
ures 3D, 3E, S3C, and S3D). Finally, and consistent with the
results in the other insulin-resistant rodent models of NAFLD,
DNPME treatment caused a marked reduction in both liver and
muscle TAG content (Figures 3F and 3G), without any indicationCell Mof renal or hepatic histopathology (Figures S1E and S1F). To
further test the assertion that DNPME treatment ameliorates hy-
perglycemia in a rat model of chronic type 2 diabetes, we per-
formed 5-day DNPME treatment studies on Zucker Diabetic
Fatty rats concurrently fed a high-fat diet and sucrose-supple-
mented drinking water. Similar to the results in the T2D model
previously described, DNPME treatment resulted in reductions
in fasting plasma glucose, insulin, and liver triglycerideetabolism 18, 740–748, November 5, 2013 ª2013 Elsevier Inc. 743
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Figure 3. Daily 5 mg/kg DNPME Reverses
Hyperglycemia, Hypertriglyceridemia, and
Hepatic Steatosis in a Low-Dose-Strepto-
zotocin-Treated, 3-Day High-Fat-Fed Rat
Model of Type 2 Diabetes
(A) Randomplasma glucose concentrations during
DNPME treatment.
(B and C) Fasting plasma glucose (B) and TAG (C).
(D and E) Concentrations of plasma glucose (D)
and insulin (E) in an intraperitoneal glucose toler-
ance test.
(F and G) TAG in liver (F) and quadriceps (G). For all
panels, n = 4–7 per group. Rats were fasted
overnight before each study. Data are represented
as mean ± SEM. In the panels comparing chow,
vehicle-treated, and DNPME-treated rats, com-
parisons were by ANOVA. See also Figure S3.
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Effect of Liver-Targeted Mitochondrial Uncouplingconcentrations, with no indication of liver or renal dysfunction
(Figures S3G–S3O).
In order to examine the impact of DNPME on whole-body
energy expenditure and other metabolic parameters, we per-
formed metabolic cage studies in DNPME- and vehicle-treated
mice. Interestingly, we observed no effects of DNPME (5 mg/
kg per day) on whole-body oxygen consumption, carbon dioxide
production, energy expenditure, respiratory quotient, or activity
(Figures S4A–S4E). Consistent with the rat studies, we also
observed no effect of DNPME on food intake (Figure S4F). Taken
together, these data suggest that DNPME at a dose of 5 mg/kg
per day promotes subtle increases in hepatic energy uncoupling
that can result in major reductions in liver and muscle fat content
with associated reversal of liver and muscle insulin resistance
without a major impact on whole-body energy expenditure.
It is also possible that low circulating levels of DNP, derived
from hepatic conversion of DNPME to DNP by the P450 system,
promote low levels of mitochondrial uncoupling in muscle and744 Cell Metabolism 18, 740–748, November 5, 2013 ª2013 Elsevier Inc.other extrahepatic organs. In order to
examine this possibility, we assessed
the effects of DNPME and DNP on state
4 oxygen consumption in vitro and
observed an increase in oxygen con-
sumption of liver, but not brain, by
DNPME, whereas DNP promoted
increased state 4 mitochondrial oxygen
consumption in isolated mitochondria in
both tissues. In contrast, neither drug un-
coupled skeletal or cardiacmuscle or kid-
ney at the tissue concentrations
measured in the DNPME-treatment
studies (Figures S4G–S4K). These data
imply that at the dose of DNPME adminis-
tered in vivo, the mitochondrial uncou-
pling effect of DNPME appears to be
mostly restricted to the liver and can be
attributed to local conversion of DNPME
to DNP by the P450 system. These data
are consistent with the observed selec-
tive effect of DNPME to only increase
mitochondrial fat oxidation flux/VTCA fluxin liver (Figure 2P) and the higher DNP concentrations in liver
relative to skeletal muscle, heart, and brain following DNPME
treatment (Figure 4C). While kidney DNP concentrations were
similar to liver, this could be attributed to the fact that DNP is
cleared from the body mostly by renal excretion. It is also
possible that there was some renal conversion of DNPME to
DNP due to the presence of P450 in the kidney. However, in
contrast to liver, we did not observe any effects of DNPME to
increasemitochondrial fat oxidation flux/VTCA flux in kidney, sug-
gesting minimal effects of DNPME on renal mitochondrial func-
tion in vivo. In addition, we observed no differences in ATP/
AMP, ATP/ADP, or NADH/NAD+ ratios in liver and skeletal mus-
cle or in phosphorylation of hepatic AMP-activated protein
kinase (AMPK) or its downstream target acetyl coenzyme A
(CoA) carboxylase (ACC), demonstrating that DNPME is not
altering the intracellular energy charge in these tissues at this
therapeutic dose (Figures S4L–S4R); however, we cannot rule
out a small effect on peripheral tissues from either local DNPME
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Figure 4. Plasma and Tissue Kinetics of DNP and DNPME Metabolism in Chow-Fed Sprague-Dawley Rats
(A) Plasma DNP and DNPME after an i.p. injection of DNPME (5 mg/kg). Red squares, DNPME; blue circles, DNP; each point represents one animal.
(B) Liver DNP and DNPME after an injection of DNPME (5 mg/kg). Red squares, DNPME; blue circles, DNP; each point represents one animal.
(C and D) Tissue DNP (C) and DNPME (D) 4 hr after an injection of DNPME (5 mg/kg).
(E) Tissue DNP 1 hr after an injection of DNP (5 mg/kg).
(F) Plasma DNP after an injection of DNP (25 mg/kg, blue circles) or DNPME (5 mg/kg, red squares). Each point represents one animal.
(G) Plasma and tissue DNP 1 hr after injection of DNP (25 mg/kg).
(H and I) Tissue DNP (H) and DNPME (I) after 7 days of daily DNPME injections (5 mg/kg). Unless otherwise noted, n = 4 per group. Data are expressed as mean ±
SEM. See also Figure S4.
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Effect of Liver-Targeted Mitochondrial Uncouplingconversion to DNP or uncoupling by circulating DNP generated
in the liver but released to the systemic circulation.
In order to gain further insight into why DNPME does not result
in hyperthermia, whereas DNP does, we measured plasma and
tissue levels of DNP and DNPME by liquid chromatography-tan-
demmass spectrometry (LC-MS/MS). We found that dosing rats
with 5 mg/kg DNPME resulted in peak plasma DNP concentra-
tions of5 mMand peak liver DNP concentrations of8 mM (Fig-
ures 4A and 4B). DNP concentrations in all tissues were below
10 mM, while DNPME accumulated in WAT, but not any other tis-Cell Msue (Figures 4C and 4D). In contrast, we found that the same
dose of DNP (5 mg/kg) resulted in a peak plasma DNP concen-
tration of 120 mM and a peak DNP liver concentration of
60 mM (Figure 4E). In order to determine how these plasma
concentrations of DNP compare with toxic levels of DNP, we
also examined plasma and liver concentrations of DNP at the
lowest dose of DNP (25 mg/kg) where systemic toxicities are
observed and found peak plasma DNP concentrations to be
380 mM (Figures 4F and 4G). Importantly, a week of DNPME
treatment resulted in tissue DNP and DNPME concentrationsetabolism 18, 740–748, November 5, 2013 ª2013 Elsevier Inc. 745
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Effect of Liver-Targeted Mitochondrial Uncouplingsimilar to those following a one-time DNPME injection (Figures
4H and 4I). Further kinetics studies would be required to estab-
lish conclusively that the improved safety of DNPME versus DNP
is purely the result of reduced DNP concentrations with DNPME
treatment, but our data are consistent with this hypothesis. Our
data also suggest that very low intracellular concentrations of
DNP, which are more than 75-fold lower than toxic levels of
DNP (380 mM), are sufficient to achieve significant liver mito-
chondrial uncoupling, resulting in reductions in ectopic lipid con-
tent and hepatic triglyceride export as well as reversing liver and
muscle insulin resistance without resulting in hyperthermia and
associated systemic toxicities.
In summary, we have demonstrated that DNPME can safely
reverse hepatic steatosis, hypertriglyceridemia, and insulin resis-
tance in a ratmodel of NAFLDwithout inducing hyperthermia and
associated hepatic and systemic toxicities. We also found that
DNPME reduces fasting plasma glucose concentrations and im-
proves glucose tolerance in two rat models of T2D. Taken
together, these data demonstrate the potential feasibility of dis-
associating the toxicity of DNP from its efficacy by altering the
pharmacokinetics of DNP metabolism to treat the related epi-
demics of NAFLD, metabolic syndrome and type 2 diabetes.
EXPERIMENTAL PROCEDURES
General Experimental Procedures for Chemical Synthesis
Chemicals were obtained from commercial sources and used as received,
unless noted otherwise. In particular, 2,4-dinitrophenol (DNP; 1) was pur-
chased from MP Biomedicals, 2,4-dinitrophenyl methyl ether (DNPME; 2)
from Alfa Aesar, and 1-chloro-2,4-dinitrobenzene-d3 (3) from C/D/N Isotopes.
For detailed information on the synthesis and analysis of the unique com-
pounds, please see the Supplemental Experimental Procedures.
Screening of Candidate Compounds
To screen candidate compounds, the ability of these compounds to raise ox-
ygen consumption rates in vivo was assessed using the Extracellular Flux
Analyzer (Seahorse Bioscience). Primary hepatocytes were isolated by the
Yale Liver Center as previously described (Neufeld, 1997) and plated on a
collagen-coated 24-well plate (Seahorse Bioscience). After a 6 hr incubation,
cells were transferred to the Seahorse XF Analyzer for measurement of oxygen
consumption rate. Basal oxygen consumption was measured, then sequential
additions of DNP (positive control) or the candidate compounds raised the
concentration of the putative uncoupler to 10, 100, 500, and 1,000 mM. Abso-
lute oxygen consumption rates were normalized to the oxygen consumption
rate measured before the first addition of uncoupler.
Animals
Male Sprague-Dawley and Zucker Diabetic Fatty rats were purchased from
Charles River Laboratories, and male C57BL/6J mice were purchased from
Jackson Laboratory. All protocols were approved by the Yale University
School of Medicine Animal Care and Use Committee.
Unless otherwise noted, animals were fed normal chow (Harlan, diet 2018).
Where specified, animals were fed 60% fat, safflower oil-based high-fat diet
(Dyets). All animals had ad libitum access to water. Where specified, caloric
intake was enriched by free access to 5% sucrose water. To measure caloric
intake, the volume of water and weight of food consumed each day were
measured, and calorie content was calculated using the known composition
of each item. Rats underwent surgery under isoflurane anesthesia to place
catheters in the jugular vein and internal carotid artery. All animalswere allowed
to recover for at least 1 week before any further experiments were performed.
To induce diabetes, rats were injected with 75 mg/kg nicotinamide and,
following a 15 min wait, 60 mg/kg streptozotocin. Animals were allowed to
recover for 3 days, and those with random plasma glucose between 150
and 350 mg/dl were used for further study. At this time, high-fat diet and746 Cell Metabolism 18, 740–748, November 5, 2013 ª2013 Elseviersucrose water feeding was initiated. After 3 days of feeding, two weeks of daily
DNPME or vehicle injections were begun.
Toxicity Studies
For the acute toxicity studies, rats were treated with an i.p. injection of various
doses of DNPME. Rectal temperature was measured with a microprobe ther-
mometer (Physitemp Instruments) at intervals up to 2 hr after injection of the
drug. Rectal temperature was measured weekly in a separate group of rats in-
jected daily with DNPME or vehicle for 6 weeks. A separate group of rats was
injected with increasing doses of DNP or DNPME in 100%DMSO to determine
the LD50.
To assess renal and hepatic toxicity, a group of catheterized rats was
treatedwith an i.p. injection of DMSO vehicle or varying doses of DNPMEdaily.
After 5 days, the rats were sacrificed, and plasma was obtained from the
intravenous catheter. The COBAS Mira Plus (Roche Diagnostics) was used
to measure plasma alanine aminotransferase (ALT), aspartate aminotrans-
ferase (AST), and blood urea nitrogen (BUN), and creatinine was measured
by LC-MS/MS. Daily creatinine clearance was measured by housing rats
treated with DNPME or vehicle in metabolic cages for 24 hr, collecting the
urine, and measuring urine creatinine by LC-MS/MS.
Histology Studies
Liver and kidney samples were prepared and stained with hematoxylin and
eosin by the Yale Research Histology core and analyzed as described (Kleiner
et al., 2005).
Glucose Tolerance Tests
Following an overnight fast, rats with a jugular venous line were injected with a
1 g/kg intraperitoneal bolus of 50% dextrose. Plasma glucose following the in-
jection was measured enzymatically on the YSI 2700 SELECT Biochemistry
Analyzer (YSI Life Sciences), and plasma insulin was measured by radioimmu-
noassay. Area under the curve (AUC) was measured from time point A to
subsequent time point B according to the following formula:
AUCA/B =
1
2
ðPlasma glcA +Plasma glcBÞ3 ðTimeB  TimeAÞ
The total area under the curve was calculated by adding the area under the
curve of all time periods. The insulin area under the curve was calculated in the
same way.
Basal and Insulin-Stimulated Glucose Turnover Studies
Hyperinsulinemic-euglycemic clamps were performed, and basal and insulin-
stimulated glucose turnover were measured using [6,6]2H2 glucose as previ-
ously described (Erion et al., 2013). To measure insulin-stimulated glucose
uptake in heart and quadriceps muscle, [14C]2-deoxyglucose was injected at
the conclusion of the clamp, and tissues were processed as described previ-
ously (Samuel et al., 2007).
nProtein Kinase C Translocation
PKCε translocation in liver and PKCq translocation in muscle from 6 hr fasted
rats in the NAFLD treatment study were measured by western blot as reported
by Choi et al. (2007).
Lipid Concentration Assays
TAG in liver and quadriceps muscle was extracted by the method of Bligh and
Dyer (1959) and measured spectrophotometrically with triglyceride reagent
(Diagnostic Chemicals Limited [DCL]). Liver and quadriceps DAG was ex-
tracted by homogenization in a buffer containing 20 mM Tris-HCl, 1 mM
EDTA, 0.25 mM EGTA, 250 mM sucrose, 2 mM phenylmethylsulfonyl fluoride,
and a protease inhibitor mixture (Roche). The cytosolic fragment was isolated
from the supernatant after high-speed centrifugation for 1 hr. DAG and cer-
amide content wasmeasured by LC-MS/MS (Yu et al., 2002). Liver triglyceride
export was measured as we have described (Lee et al., 2011).
Measurement of Liver Glycogen Content
Hepatic glycogen content was assessed by amyloglucosidase digestion using
the method of Passonneau and Lauderdale (1974).Inc.
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Effect of Liver-Targeted Mitochondrial UncouplingAssessment of Plasma Metabolites, Adipocytokines, and
Inflammatory Markers
Plasma concentrations of 12 inflammatory markers were measured by ELISA
(QIAGEN). Adiponectin was measured by radioimmunoassay. Lactate was
measured by COBAS and FGF-21 by ELISA (Millipore).
Assessment of Basal Metabolism in Mice
Mice were studied during daily i.p. injections of 5 mg/kg DNPME or vehicle.
Comprehensive Animal Metabolic Monitoring System (Columbus Instruments)
was used to measure oxygen uptake and carbon dioxide production, daily
caloric intake and energy expenditure, respiratory exchange ratio, and activity.
Evaluation of Hepatic Flux Rates in Rats
To measure liver-specific flux through the TCA cycle, we performed a steady-
state infusion of [3-13C] lactate (5 min prime 120 mmol/[kg  min], 115 min
continuous infusion of 40 mmol/[kg  min]) and [3H] glucose (44 mmol/min).
At 120min, plasma and livers were isolated, and hepatic fluxes weremeasured
by nuclear magnetic resonance (NMR) and LC-MS/MS as described in the
Supplemental Experimental Procedures.
Measurement of Plasma and Tissue DNP and DNPME
Concentrations
Plasma (10–100 ml) or tissue (100 mg) was mixed with 2.0 ml prechilled chlo-
roform/methanol (v/v: 2/1) containing 0.01% butylated hydroxytoluene (BHT)
in 5 ml glass vials, then 250 ml water was mixed with 10 nmol DNP-D3 and
10 nmol DNPME-D6 as the internal standards. The mixtures were vortexed,
centrifuged, and the bottom organic layer was carefully collected and dried
with a steady stream of nitrogen gas, then reconstituted in 200 ml methanol
for LC-MS/MS analysis. Analysis of DNP and DNPME was performed by LC-
MS/MS using an Applied Biosystems 4000 QTRAP with Shimadzu ultrafast
HPLC and electrospray ionization source with negative ion detection. The
quantitative analysis of DNP was monitored in multiple reaction monitoring
(MRM) mode with an ion pair (183.0/109.0). A Hibar LiChrosorb Analytical
HPLC column (RP-C8, 4 3 125 mm, particle size 5 mM) (Merck KGaA) was
used to separate DNP and DNPME using an isocratic flow of 15% 10 mM
ammonium formate and 85% methanol/water (95/5). The retention time is
4 min for DNP and 7 min for DNPME.
Kinetics Studies
To evaluate the kinetics of DNP and DNPME, a 5 mg/kg dose of DNPME
was injected at time zero. Rats were sacrificed at 1, 2, 4, 6, 12, and 24 hr
to isolate the liver, and plasma was drawn through a venous catheter at
each time point.
To compare tissue concentrations of DNPME andDNPwith various injection
protocols, separate groups of rats (n = 4 per group) were treated with 5 mg/kg
DNPME, 5 mg/kg DNP, or 25 mg/kg DNP. The DNPME-injected rats were
sacrificed 4 hr after the last injection, while the DNP-injected rats were sacri-
ficed 1 hr after the last injection, whichwas found to represent the peak plasma
concentrations of DNP with the respective injections.
Mitochondrial Respiration Studies
Isolated mitochondria from liver and brain of overnight-fasted rats were pre-
pared (Andrews et al., 2008), and respiration was measured on the Seahorse
XF Analyzer. Additional details may be found in the Supplemental Experi-
mental Procedures.
Assessment of Tissue Energetics
Tomeasure tissue ATP, ADP, AMP, NADH, and NAD+ concentration, rats were
sacrificed by decapitation, and metabolites of interest were extracted and
measured by LC-MS/MS as described in the Supplemental Experimental
Procedures.
Statistical Analysis
All data are expressed asmean ± SEM. Significance was determined using the
two-tailed unpaired Student’s t test or, if indicated, by the two-tailed paired
Student’s t test or ANOVA. Differences with a p value less than 0.05 were
considered significant.Cell MSUPPLEMENTAL INFORMATION
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